185098-72-0

Upstream product

• 100-42-5 styrene 
• 67-56-1 methanol 
• 185098-76-4 2-bromo-1-phenylethyl cyanamide 

Downstream Products

• 185098-53-7 1-(Indane-5-sulfonyl)-2-methoxy-4-phenyl-4,5-dihydro-1H-imidazole 
• 185098-63-9 1-(Indane-5-sulfonyl)-2-methoxy-5-phenyl-4,5-dihydro-1H-imidazole 
• 185098-52-6 1-(4-Chloro-benzenesulfonyl)-2-methoxy-4-phenyl-4,5-dihydro-1H-imidazole 
• 1314774-36-1 ethyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-47-4 2,2,2-trifluoro-1-(6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)ethanone 
• 1314774-34-9 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-1,2,3,4-tetrahydroquinoline 
• 1314774-35-0 methyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-37-2 propyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-38-3 isobutyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-40-7 butyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-41-8 allyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-43-0 2-chloroethyl 6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
• 1314774-44-1 2-chloro-1-(6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)ethanone 
• 1314774-46-3 (6-(2-methoxy-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)(phenyl)methanone 

Relevant academic research and scientific papers

Structure-activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity

To define the SAR, a series of novel N-arylsulfonylimidazolidinone derivatives were evaluated for their in vitro anticancer activity against five human tumor cell lines, including A549, COLO205, KATO III, K562, SK-OV-3 and murine leukemia (P288D1) cell line. Among them, N-(2-chloroacetyl)-6-(2-oxo-4- phenylimidazolidin-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxamide (4m) and N-cyclohexyl-6-(2-oxo-4-phenylimidazolidin-1-ylsulfonyl)-3,4-dihydroquinoline- 1(2H)-carboxamide (4n) exhibited comparable in vitro anticancer activity to doxorubicin against A549, KATO III and K562 cell lines and gave superior xenographic results against NCI-H23 and SW620 cancer cell lines. Regarding the structure-activity relationship, two critical points were discovered; the steric congestion at 4-position of N-arylsulfonylimidazolidinone scaffold abolishes the activity and the bulkiness or hydrophobicity of acyl groups at 3,4-dihydroquinoline of 4, especially with carbamoyl moiety, enormously enhances the activity.

Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones

Synthesis of novel arylsulfonylimidazolidinones 3 and 4 containing sulfonylurea pharmacophore and evaluation of their in vitro cytotoxicity against human cell lines were investigated. As a result, a series of 4-phenyl-1(N)-arylsulfonylimidazolidinones have been found to be the potential anticancer agent.